WO2020004989A1 - Composition pour la prévention, l'amélioration ou le traitement de la cachexie comprenant du kimchi - Google Patents

Composition pour la prévention, l'amélioration ou le traitement de la cachexie comprenant du kimchi Download PDF

Info

Publication number
WO2020004989A1
WO2020004989A1 PCT/KR2019/007836 KR2019007836W WO2020004989A1 WO 2020004989 A1 WO2020004989 A1 WO 2020004989A1 KR 2019007836 W KR2019007836 W KR 2019007836W WO 2020004989 A1 WO2020004989 A1 WO 2020004989A1
Authority
WO
WIPO (PCT)
Prior art keywords
kimchi
cachexia
kelp
weight
mushroom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2019/007836
Other languages
English (en)
Korean (ko)
Inventor
함기백
한영민
박용진
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gimedics Co ltd
Industry Academic Cooperation Foundation of College of Medicine Pochon CHA University
Original Assignee
Gimedics Co ltd
Industry Academic Cooperation Foundation of College of Medicine Pochon CHA University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gimedics Co ltd, Industry Academic Cooperation Foundation of College of Medicine Pochon CHA University filed Critical Gimedics Co ltd
Publication of WO2020004989A1 publication Critical patent/WO2020004989A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B7/00—Preservation of fruit or vegetables; Chemical ripening of fruit or vegetables
    • A23B7/10—Preserving with acids; Acid fermentation
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B7/00—Preservation of fruit or vegetables; Chemical ripening of fruit or vegetables
    • A23B7/10—Preserving with acids; Acid fermentation
    • A23B7/105—Leaf vegetables, e.g. sauerkraut
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/20—Products from fruits or vegetables; Preparation or treatment thereof by pickling, e.g. sauerkraut or pickles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/758—Zanthoxylum, e.g. pricklyash
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/202—Algae extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/208—Fungi extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Definitions

  • the present invention relates to a composition for preventing, improving or treating cachexia including kimchi.
  • Cachexia is a highly systemic disorder in the late stages of tuberculosis, hemophilia, and cancer. It is a humoral pathological disorder that places the nature of the disease in the modulation of body fluids, sometimes defined as weight loss of at least 5% within 12 months. In addition, it is regarded as a kind of poisoning state caused by various organ disorders of the whole body, and the symptoms include rapid bleeding, anemia, lethargy, and skin yellowing.
  • the causative agent of cachexia is known to be a malignant tumor, Vasedou's disease, hypothalamus function, and bioactive substances such as tumor necrosis factor (TNF) produced by macrophages have been found to enhance cachexia.
  • TNF tumor necrosis factor
  • Cancer cachexia occurs in about one third of all patients with cancer and is estimated to be a direct cause of death in up to 20% of all cancer-related deaths.
  • Patients with solid tumors, colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) have a relatively high incidence of cachexia of about 28% and 34%, respectively.
  • Kimchi is a salted fermented food of Korea's representative vegetables, which is made by salting vegetables such as radish, cabbage, cucumber, and soaking various spices such as red pepper, green onion, garlic, and ginger.
  • Korean kimchi is unique in different regions and families. In particular, according to the fat, the characteristics of the red pepper powder and the type of salted fish are produced. In the cold regions of the north, white kimchi, bossam kimchi, and Dongchimi, which use less red pepper powder, are famous, and spicy kimchi in Honam province and salty kimchi in Yeongnam province.
  • kimchi as an appropriate dietary supplement or therapeutic agent
  • proper adjustment of the components of kimchi and its combination is necessary.
  • suitable kimchi as a dietary supplement or therapeutic agent that can improve or inhibit the progression of cachexia symptoms such as weight loss.
  • Another object of the present invention is to provide a food composition for cachexia prevention or improvement, including kimchi, including fresh, sancho, pear, mushroom and kelp.
  • Still another object of the present invention is to provide a use of kimchi, including freshly prepared, sancho, pear, mushroom and kelp, for the manufacture of a medicament for preventing or treating cachexia.
  • Still another object of the present invention is to provide a method for preventing or treating cachexia comprising administering to a subject kimchi including freshly prepared, wild vinegar, pear, mushroom and kelp.
  • Still another object of the present invention is to provide a use of kimchi, including mustard, cabbage, pear, mushroom and kelp, for preventing or treating cachexia.
  • the present inventors have made efforts to prevent, improve, or treat cachexia, a high disease associated with high systemic weakness, using kimchi, which is one of the foods easily available in a normal diet, and thus, in the composition of commonly used kimchi, It was confirmed that the kimchi, including fresh, sancho, pears, mushrooms and kelp further have a significant effect on the prevention, improvement and treatment of cachexia and completed the present invention.
  • composition according to the present invention inhibits weight loss in cachexia, minimizes weight loss despite low food intake, reduces tumor size and volume, one of the causes of cachexia, regulates inflammatory factors, muscle atrophy By regulating the relevant protein expressions it has a significant effect on the prevention, improvement and treatment of cachexia.
  • composition for preventing or treating cachexia including kimchi, including freshly prepared, Japanese pepper, pear, mushroom, and kelp
  • the present invention provides a pharmaceutical composition for cachexia prevention or treatment, including kimchi, including fresh, sancho, pear, mushroom and kelp.
  • cancer cachexia refers to a systemic state of weakness including symptoms such as weight loss, physical strength, anemia, indigestion, and the like caused by tuberculosis, hemophilia, and cancer.
  • cancer cachexia which means that the cancer loses most of the nutrients to the tumor, weight loss, physical strength decreases, thereby leading to systemic weakness.
  • prevention means any action that inhibits or delays cachexia by administering or ingesting a composition of the present invention to a subject.
  • treatment refers to any action to improve or benefit from cachexia by administering or ingesting a composition of the present invention to a subject.
  • the term "kimchi” refers to salted fermented foods prepared by salting vegetables such as radishes and cabbages and mixing various spices such as pepper, green onions, garlic and ginger.
  • the term "gat" is a plant belonging to the mustard family 1 year, 2 years. Preferably a Mustard leaf leaf is used.
  • Chiinese Pepper refers to a bark of a horticulture or bark of the same plant, prepared by removing seeds as much as possible.
  • pear in the present invention is the fruit of the genus Pear. It is preferably a southern oriental pear mainly cultivated in Korea and Japan.
  • the term "mushroom” is the fruiting body of edible bacteria. Preferably shiitake mushrooms or extracts thereof.
  • the term "sea tangle" is a kind of edible brown algae. Preferably kelp or extract thereof.
  • extract in the present invention, regardless of the extraction method, means a formulation squeezed the object to a suitable leach solution or a formulation concentrated by evaporating the squeezed leach solution, but is not limited to, extracts obtained by extraction treatment, It is a concept containing the diluted or concentrated liquid of an extract, the dried material obtained by drying an extract, these refiners, or the like.
  • the shade may comprise 1.0 to 10.0% by weight relative to the total weight of kimchi.
  • the sancho may include 0.05 to 0.5% by weight relative to the total weight of kimchi.
  • the belly may include 1.0 to 5.0% by weight relative to the total weight of kimchi.
  • the mushroom may include 1.0 to 5.0% by weight based on the total weight of kimchi.
  • the kelp may be included in an amount of 1.0 wt% to 5.0 wt% based on the total weight of kimchi.
  • conventional kimchi includes at least one selected from the group consisting of, for example, Chinese cabbage, red pepper powder, garlic, ginger, radish, green onion, and sugar.
  • Common kimchi includes cabbage, red pepper powder, garlic, ginger, radish, green onions and sugar.
  • the pharmaceutical composition according to the present invention is added to the kimchi containing freshly, Sancho, pears, mushrooms and kelp as kimchi containing Chinese cabbage, red pepper powder, garlic, ginger, radish, green onions and sugar.
  • kimchi containing Chinese cabbage, red pepper powder, garlic, ginger, radish, green onions and sugar.
  • it may further include other ingredients used in kimchi.
  • 1.0 to 10.0% by weight of the total weight of kimchi 0.05 to 0.5% by weight of the total weight of kimchi, 1.0 to 5.0% by weight of the total weight of kimchi, the mushrooms, 1.0 to 5.0% by weight relative to the total weight of kimchi and 1.0 to 5.0% by weight relative to the total weight of kimchi, and may be made with a combination of other components of kimchi in an appropriate ratio. More specifically, 5 to 6% by weight of the fresh leaves of kimchi, 0.05 to 0.1% by weight of the total weight of kimchi, 1.5 to 2.5% by weight of the total weight of glyphchi, pear extract, mushroom extract and kelp extract It may include 3.0 to 4.0% by weight relative to the total weight of glyphchi.
  • kimchi can be made by including the above components in a conventional kimchi production method known in the art.
  • salted cabbage, red pepper powder, garlic, ginger, radish, green onion a little sugar can be mixed and fermented while adding leaf, pepper, pear, shiitake mushroom extract, kelp extract.
  • the kimchi includes fresh kimchi, cabbage, pears, mushrooms and kelp in addition to the usual kimchi ingredients cabbage, red pepper powder, garlic, ginger, radish, green onions and sugar.
  • Kimchi of the present invention preferably comprises kimchi at 0.1 to 95% by weight relative to the total weight of the composition, but is not limited thereto.
  • the kimchi may be provided in various forms through liquefaction, freeze-drying, freeze-drying, extraction, powdering, and solidification.
  • extract has its usual common meaning in the field of compositions, irrespective of the method of extraction, and includes both dry and liquid extracts, regardless of the form of the extract, the pulverized or subject matter of the subject itself. Dry grinding of may also be included. Also included are artificial extracts configured to mimic the composition of natural extracts. Specifically, the extract in the present invention may be a lyophilized extract.
  • compositions of the invention may be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method.
  • oral administration refers to a method of injecting a medicament for improving pathological symptoms
  • parenteral administration refers to subcutaneous, intramuscular, intravenous, It means a method to be administered intraperitoneally using a tube.
  • the pharmaceutical composition of the present invention may be preferably orally administered to mammals such as rats, mice, livestock, humans, and the like.
  • compositions of the present invention may comprise a pharmaceutically acceptable carrier and may be formulated in the form of oral dosage forms, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, etc., according to conventional methods, respectively. .
  • Such pharmaceutically acceptable carriers are those commonly used in the art, such as lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
  • the pharmaceutical compositions of the present invention include diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, and other pharmaceutically acceptable additives.
  • the pharmaceutical composition of the present invention when formulated as an oral solid preparation, it includes tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, Sucrose or lactose, gelatin, and the like, and include, but are not limited to, lubricants such as magnesium stearate, talc, and the like.
  • the pharmaceutical composition of the present invention when formulated for oral liquid preparation, it includes a suspending agent, a liquid solution, an emulsion, a syrup, and the like, and includes, but is not limited to, diluents such as water and liquid paraffin, wetting agents, sweeteners, fragrances, preservatives, and the like.
  • Formulations for parenteral administration may be formulated in the form of sterile aqueous solutions, liquids, non-aqueous solutions, suspensions, emulsions, eye drops, ophthalmic ointments, syrups, suppositories, aerosols, etc., and sterile injectables, respectively, according to conventional methods. It can be used to prepare a pharmaceutical composition of creams, gels, patches, sprays, ointments, warnings, lotions, linings, eye ointments, eye drops, pasta or cataplasma However, the present invention is not limited thereto. Compositions of topical administration may be anhydrous or aqueous, depending on the clinical prescription.
  • non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the dosage of the whole composition including fresh, cabbage, pear, mushroom, and kelp contained in the pharmaceutical composition of the present invention in kimchi depends on the patient's condition and weight, age, degree of disease, type of drug, route of administration, and duration. It may be appropriately selected by those skilled in the art.
  • kimchi prepared with freshly prepared, wild pepper, pear, mushroom and kelp may be administered at a dose of 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg, per day. It may be administered once or several times a day.
  • Food composition for preventing or improving cachexia including kimchi, including freshly prepared, cabbage, pear, mushroom, and kelp
  • the present invention also provides a food composition for preventing or improving cachexia, including kimchi, including freshly prepared, sancho, pear, mushroom, and kelp.
  • improvement in the present invention means any action that improves the bad state of cachexia by administering or ingesting the composition of the present invention to a subject.
  • the present invention can be generally used as a commonly used food. It can also be used in addition to the fresh kimchi, vinegar, pears, mushrooms and kelp in addition to the various conventional kimchi ingredients without any additional ingredients.
  • kimchi is added to the kimchi containing freshly, Sancho, pears, mushrooms and kelp as kimchi ingredients including Chinese cabbage, red pepper powder, garlic, ginger, radish, green onions and sugar.
  • the food composition according to the present invention can be used as a health functional kimchi.
  • 1.0 to 10.0% by weight of the total weight of kimchi, 0.05 to 0.5% by weight of the total weight of kimchi, 1.0 to 5.0% by weight of the total weight of kimchi, and the mushrooms to the total weight of kimchi 1.0 to 5.0% by weight and the kelp may be included in 1.0 to 5.0% by weight relative to the total weight of kimchi, and other components of kimchi may be prepared by combining the components of the kimchi in an appropriate ratio.
  • the food composition of the present invention can be used as a dietary supplement.
  • health functional food means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to the Act on Health Functional Foods, and the term “functional” means It means ingestion for the purpose of obtaining useful effects on health use such as nutrient control or physiological action on structure and function.
  • the food composition of the present invention may include a conventional food additive, and the suitability as the "food additive" is applicable according to the General Regulations and General Test Law of the Food Additives approved by the Ministry of Food and Drug Safety unless otherwise specified. Judge according to the standards and standards for the item.
  • Food Additives Revolution examples include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamon acid, natural additives such as color pigments, licorice extract, crystalline cellulose, high color pigments, guar gum, Mixed preparations, such as a sodium L- glutamate preparation, an addition of an alkali, a preservative preparation, and a tar pigment preparation, are mentioned.
  • chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamon acid
  • natural additives such as color pigments, licorice extract, crystalline cellulose, high color pigments, guar gum
  • Mixed preparations such as a sodium L- glutamate preparation, an addition of an alkali, a preservative preparation, and a tar pigment preparation, are mentioned.
  • the food composition of the present invention may include from 0.01 to 100% by weight, preferably 5 to 99% by weight of kimchi including fresh, sancho, pear, mushroom and kelp relative to the total weight of the composition.
  • the food composition of the present invention may be prepared and processed in the form of tablets, capsules, powders, granules, liquids, pills, and the like for the purpose of preventing and / or improving cachexia as well as using kimchi itself.
  • the nutraceutical in the form of tablets may be prepared by granulating a mixture with freshly prepared, fresh, vinegar, pear, mushroom and kelp according to the present invention, excipients, binders, disintegrants, and other additives in a conventional manner. Compression molding may be performed by adding a lubricant, or the mixture may be directly compression molded.
  • the health functional food in the form of tablets may contain a mating agent and the like, if necessary, may be coated with a suitable coating agent.
  • soft capsules can be prepared by filling a capsule base such as gelatin mixture with additives such as food compositions and excipients according to the present invention.
  • the soft capsule may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, as necessary.
  • the health functional food in the form of a cyclic form may be prepared by molding a mixture of freshly prepared, fresh pepper, pear, mushroom and seaweed including kimchi, excipient, binder, disintegrating agent, etc. according to the present invention. It can also be coated with a coating agent or with starch, talc or a suitable substance.
  • the health functional food in the form of granules can be prepared by granulating a mixture of kimchi, excipients, excipients, binders, disintegrants and the like according to the present invention, freshly prepared, vinegar, pear, mushroom and kelp according to the present invention. It may contain an agent and the like.
  • No. 12 (1680 ⁇ m), No. 14 (1410 ⁇ m) and No. 45 (350 ⁇ m) were used for the next particle size test. Less than 5.0% and passing through No. 45 may be less than 15.0% of the total amount.
  • excipients binders, disintegrants, glidants, copulation agents, flavoring agents, etc. are described in the literature known in the art and include those having the same or similar functions (Korean Pharmacopoeia, Munseongsa, Korea Pharmacy University Council, 5th edition, p33-48, 1989).
  • the present invention provides a method for preventing or treating cachexia comprising administering kimchi to a subject, including freshly prepared, wild pepper, pear, mushroom, and kelp.
  • the subject may refer to an animal, and may be a mammal, which may typically have a beneficial effect with treatment with kimchi, including the lampshade, pepper, pear, mushroom and kelp of the present invention.
  • Preferred examples of such subjects may include primates, such as humans.
  • such subjects may include all subjects having or having a risk of cachexia.
  • the composition for preventing or treating cachexia including kimchi including the lampshade, sancho, pear, mushroom and kelp of the present invention is oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, Administration can be in conventional manner via intrasternal, transdermal, topical, intraocular or intradermal routes.
  • the term “therapeutically effective amount” means an amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, as contemplated by a researcher, veterinarian, doctor or other clinician. Which includes amounts that induce alleviation of the symptoms of the disease or disorder being treated. It will be apparent to those skilled in the art that the therapeutically effective dosages and frequency of administrations for the active ingredients of the present invention will vary depending on the desired effect. Therefore, the optimal dosage to be administered can be readily determined by one skilled in the art and includes the type of disease, the severity of the disease, the amount of active ingredients and other ingredients contained in the composition, the type of formulation, and the age, weight, general health of the patient.
  • the pharmaceutical composition for cachexia prevention or treatment comprising kimchi including the freshly prepared, wild pepper, pear, mushroom and kelp of the present invention, once a week to several times, 0.001 mg It may be administered at a dose of / kg to 10 mg / kg, but is not limited thereto.
  • the present invention also provides the use of kimchi, including mustard, cabbage, pear, mushroom and kelp, for the manufacture of a medicament for preventing or treating cachexia.
  • the composition comprising kimchi, including freshly prepared, medicinal herbs, pears, mushrooms and kelp for the manufacture of a medicament may be mixed with an acceptable carrier, and may further comprise other agents have.
  • kimchi including mustard, cabbage, pear, mushroom, and kelp, for the prevention or treatment of cachexia
  • the present invention also provides the use of kimchi, including mustard, pepper, pear, mushroom and kelp, for the prevention or treatment of cachexia.
  • the composition comprising kimchi, including fresh, sancho, pear, mushroom and kelp for the prevention or treatment of cachexia may be mixed with an acceptable carrier, and further comprises other agents You may.
  • composition according to the invention inhibits weight loss in cachexia, minimizes weight loss despite low food intake, reduces the size and volume of tumors, one of the causes of cachexia, and regulates the expression of inflammatory factors It is expected to be useful for preventing, improving and treating cachexia because it has an effect of relieving muscle loss caused by cachexia by regulating muscle atrophy related protein expression.
  • 1 is an experimental schedule for preparing a cachexia animal model and confirming the prevention, improvement and treatment effect of kimchi according to the present invention.
  • Figure 2 shows the results of confirming the weight change by day in cachexia animal model.
  • Figure 4 shows the results of confirming the change in feed intake by parking in the cachexia animal model.
  • Figure 5 shows the results of confirming the change in tumor size by parking in cachexia animal model.
  • Figure 6 shows the results of confirming the average tumor volume change in cachexia animal model.
  • Figure 7 shows the result of confirming the degree of hind limb muscle loss in cachexia animal model.
  • TNF- ⁇ tumor necrosis factor- ⁇
  • IL-6 interleukin
  • Salted Chinese cabbage, red pepper powder, garlic, ginger, radish, green onion, some sugar, including kimchi leaves were prepared by fermentation by adding the leaves, pepper, pear, shiitake mushroom extract, kelp extract.
  • Shiitake extract used herein is heated and filtered into a five-mushroom in 1 L of water was allowed to stand overnight and then for 5 seconds, will use the extract has been removed is shiitake, filtered, and kelp extract is 2 X 3 cm 2 size 5 pieces of kelp were placed in 1 L of water, left overnight, and then heated for about 5 seconds and then filtered to remove kelp.
  • Kimchi was freeze-dried and made into fine kimchi powder and then stirred overnight to extract methanol to prepare a kimchi methanol extract, which was concentrated by evaporation (BRE 111 rotavapor, Switzerland) and stored at 4 ° C for use in the test. .
  • C26 adenocarcinoma cell line BALB / c mice (male, 6 weeks old) used for this study were bred on an experimental diet for at least 3 weeks. The experimental group was divided into normal group and control group (Control: C26 cell subcutaneous injection). C26 adenocarcinoma cell line was incubated in 37 ° C cell culture in RPMI-1640 medium (Sigma) containing 10% Fetal bovine serum. Survival was more than 3 weeks after 1 ⁇ 10 7 injections of C26 adenocarcinoma cell lines. Kimchi extract administration group was administered Kimchi extract via intraperitoneal Administration (IP) once a week at a concentration of 5.0 mg / kg.
  • IP intraperitoneal Administration
  • the tumor size and the amount of hind limb muscle loss formed were measured after the tumor was removed and the average size (mm 2 ) and average volume (mm 3 ) of the tumor were measured using a Mitutoyo caliper. .
  • FIG. 5 shows tumor size change by parking. As confirmed in FIG. 5, it was confirmed that the tumor size was significantly smaller than the control group in both the 2nd and 3rd weeks. Based on this result of confirming the average tumor volume is shown in Figure 6, as shown in Figure 6 it was confirmed that the average tumor volume is also smaller in the kimchi extract administration group than the cachexia induction group.
  • the kimchi extract according to the present invention has an excellent effect in the treatment of symptoms such as muscle loss caused by cachexia.
  • RNA was extracted using TRIzol (Gibco BRL, Rockville, MD, USA), and the extracted RNA was synthesized into cDNA using a cDNA synthesis kit (TOYOBO).
  • TOYOBO cDNA synthesis kit
  • Each Primer sequence used for PCR analysis is shown in Table 2, and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal standard.
  • Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal standard.
  • Real time PCR was performed using SYBR Premix EX TaqTM Tli RNase H plus (TAKARA).
  • Primer Information primer Forward Reverse IL-6 ccggagagag gagacttcac ag (SEQ ID NO: 1) tccacgattt cccagagaac (SEQ ID NO: 2) TNF- ⁇ ggaactggca gaagaggcac tc (SEQ ID NO: 3) gcaggaatga gaagaggctg agac (SEQ ID NO: 4) Atrogin-1 agattcgcaa gcgtttgatc (SEQ ID NO: 5) gggaaagtga gacggagcag (SEQ ID NO: 6) MuRF1 cctctctagg ccaccgagt (SEQ ID NO: 7) tggcgattgt cacaaagtgg (SEQ ID NO: 8) GAPDH cagggcaaat tcaacggcac agtcaa (SEQ ID NO: 9) gttcacaccc atcacaaa
  • Figure 8 shows the results of confirming the expression changes of Atrogin-1 and MuRF-1 as factors associated with muscle atrophy. As confirmed in Figure 8, it was confirmed that the expression of Atrogin-1 and MuRF-1 in the kimchi extract administration group according to the present invention compared to the cachexia induced group, through which the kimchi extract of the present invention is associated with muscle atrophy It was confirmed that the treatment and improvement effect. (Normal: normal, Cachexia: cachexia-induced group, cpKimchi: kimchi extract group)
  • the composition according to the invention inhibits weight loss in cachexia, minimizes weight loss despite low food intake, reduces tumor size and volume, one of the causes of cachexia, and expresses inflammatory factors. It has been found that it can be useful for the prevention, improvement and treatment of cachexia because it has the effect of relieving inflammation by regulating protein expression of muscle atrophy by regulating the muscle atrophy related protein expression.
  • the following formulation was prepared using kimchi including freshly prepared, Example 1, vinegar, mushroom, and kelp of Example 1.
  • kimchi including freshly prepared, Example 1, vinegar, mushroom, and kelp of Example 1.
  • the following formulation examples are merely illustrative of the present invention, whereby the content of the present invention is not limited.
  • Liquid extract after freeze drying of kimchi including freshly pickled, vinegar, pear, mushroom and kelp ;........ 1000 mg
  • Purified water was added to adjust the total volume to 1000 ml. According to the conventional method for preparing a liquid, the above components were mixed, and then filled into a brown bottle and sterilized to prepare a liquid.
  • the above ingredients were mixed and filled into gelatin capsules to prepare capsules.
  • the above functional ingredients were mixed to prepare a health functional beverage.
  • composition according to the invention inhibits weight loss in cachexia, minimizes weight loss despite low food intake, reduces the size and volume of tumors, one of the causes of cachexia, and regulates the expression of inflammatory factors It is expected to be useful for preventing, improving and treating cachexia because it has an effect of relieving muscle loss caused by cachexia by regulating muscle atrophy related protein expression.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition pour la prévention, l'amélioration ou le traitement de la cachexie comprenant du kimchi. La composition selon la présente invention a un effet significatif sur la prévention, l'amélioration et le traitement de la cachexie par l'inhibition de la perte de poids dans la cachexie, la réduction au minimum de la perte de poids malgré une faible absorption d'aliments, la réduction de la taille et du volume d'une tumeur qui est l'une des causes de la cachexie, la régulation de facteurs inflammatoires, et la régulation de l'expression de la protéine liée à l'atrophie musculaire.
PCT/KR2019/007836 2018-06-28 2019-06-27 Composition pour la prévention, l'amélioration ou le traitement de la cachexie comprenant du kimchi Ceased WO2020004989A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0074576 2018-06-28
KR1020180074576A KR20200001730A (ko) 2018-06-28 2018-06-28 김치를 포함하는 악액질 예방, 개선 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
WO2020004989A1 true WO2020004989A1 (fr) 2020-01-02

Family

ID=68987433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/007836 Ceased WO2020004989A1 (fr) 2018-06-28 2019-06-27 Composition pour la prévention, l'amélioration ou le traitement de la cachexie comprenant du kimchi

Country Status (2)

Country Link
KR (1) KR20200001730A (fr)
WO (1) WO2020004989A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102477343B1 (ko) * 2020-11-09 2022-12-13 경희대학교 산학협력단 한약복합추출물을 포함하는 악액질 예방 또는 치료용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090084589A (ko) * 2008-02-01 2009-08-05 경상북도(관련부서:경상북도산림생태과학원) 오가피를 이용한 김치, 이의 추출물 및 이를 이용한 식품또는 약제학적 조성물
KR101346161B1 (ko) * 2012-09-20 2014-01-15 송병덕 항암 기능성 김치 및 그 제조방법
KR20150022800A (ko) * 2012-05-11 2015-03-04 주식회사 카엘젬백스 악액질 예방 또는 치료용 조성물
KR20170058509A (ko) * 2015-11-18 2017-05-29 차의과학대학교 산학협력단 헬리코박터 파이로리 원인성 질병에 대한 예방 및 치료 활성을 보이는 김치
KR20170065707A (ko) * 2015-12-03 2017-06-14 농업회사법인주식회사산들 파프리카를 포함한 항암 및 항산화 기능성 김치의 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100433976B1 (ko) 2001-07-30 2004-06-04 우병천 저염도 저자극성의 김치조성물
KR20110123905A (ko) 2010-05-10 2011-11-16 경상남도 해산물을 이용한 김치양념 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090084589A (ko) * 2008-02-01 2009-08-05 경상북도(관련부서:경상북도산림생태과학원) 오가피를 이용한 김치, 이의 추출물 및 이를 이용한 식품또는 약제학적 조성물
KR20150022800A (ko) * 2012-05-11 2015-03-04 주식회사 카엘젬백스 악액질 예방 또는 치료용 조성물
KR101346161B1 (ko) * 2012-09-20 2014-01-15 송병덕 항암 기능성 김치 및 그 제조방법
KR20170058509A (ko) * 2015-11-18 2017-05-29 차의과학대학교 산학협력단 헬리코박터 파이로리 원인성 질병에 대한 예방 및 치료 활성을 보이는 김치
KR20170065707A (ko) * 2015-12-03 2017-06-14 농업회사법인주식회사산들 파프리카를 포함한 항암 및 항산화 기능성 김치의 제조방법

Also Published As

Publication number Publication date
KR20200001730A (ko) 2020-01-07

Similar Documents

Publication Publication Date Title
WO2017039365A1 (fr) Méthode d'inhibition de l'absorption et/ou de promotion de l'excrétion de lipides à l'aide de d-psicose
WO2012033378A2 (fr) Composition comprenant un extrait de cudrania tricuspidata et de coix lachryma-jobi ayant une activité anti-obésité et un effet d'abaissement du taux de sucre dans le sang, et son utilisation
EP3991742A1 (fr) Agent thérapeutique contre le coronavirus comprenant un extrait d'elaeocarpus sylvestris en tant que principe actif
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
WO2018174448A1 (fr) Composition pour le traitement et la prévention du syndrome climactérique contenant un extrait médicinal végétal combiné d'atractylis, de mori fructus, de lyciet commun, de longane, d'achyranthes, d'écorce d'eucommia et d'asperge de cochinchine merr. comme ingrédient actif, et son utilisation
WO2017014502A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par il-6 comprenant un extrait de fleur de rosa rugosa en tant que substance active
WO2022145893A1 (fr) Composition permettant de soulager le stress comprenant du noni et du calamondin fermentés et vieillis comme principes actifs
WO2017183902A1 (fr) Composition contenant des extraits de artemisia capillaris, sanguisorba officinalis et curcuma longa et un agent antiviral, en tant que principes actifs, destinée à prévenir ou traiter une maladie du foie
WO2013100340A1 (fr) Composition comprenant un extrait de dendropanax morbiferus pour améliorer la fonction sexuelle masculine
WO2016190566A9 (fr) Composition pharmaceutique ou aliment naturel fonctionnel pour la prévention et le traitement de maladies métaboliques, contenant un extrait aqueux de pleurotus eryngii var. ferulae (pf.) en tant que principe actif
WO2020004989A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de la cachexie comprenant du kimchi
WO2016190481A1 (fr) Adjuvant anticancéreux contenant un composé de ginsenocide de panaxadiol
WO2016010340A1 (fr) Composition pour prévenir et traiter l'inflammation ou les maladies allergiques contenant un extrait de gynura procumbens en tant que principe actif, et son utilisation
WO2012115469A2 (fr) Composition alimentaire fonctionnelle anti-inflammatoire à administrer par voie orale et son procédé de préparation
WO2014126285A1 (fr) Composition pour la prévention ou le traitement de la fibrose rénale, comprenant du diméthylfumarate en tant que principe actif
WO2020218727A2 (fr) Peptide isolé dans un hydrolysat de protéines du ver de farine tenebrio molitor et composition le comprenant en tant que principe actif pour prévenir ou traiter une atteinte hépatique
WO2015167240A1 (fr) Composition contenant un extrait de scutellaria alpina
KR20160108771A (ko) 능이버섯 추출물을 포함하는 간 질환의 예방 또는 치료용 조성물
WO2014007536A1 (fr) Composition pharmaceutique ayant un effet préventif ou thérapeutique sur les maladies inflammatoires de l'intestin
WO2014126269A1 (fr) Composition pharmaceutique pour améliorer la fonction sexuelle masculine et pour traiter l'infertilité
WO2024122660A1 (fr) Composition d'immunostimulation contenant un extrait de mélange végétal en tant que principe actif
WO2018008999A1 (fr) Composition comprenant un extrait d'aster koraiensis ou une fraction de ce dernier en tant que principe actif servant à la régulation de la glycémie et à la prévention ou au traitement du diabète
WO2025048076A1 (fr) Composition comprenant un extrait de fomitopsis pinicola en tant que principe actif pour le traitement ou la prévention d'une maladie cérébrale ischémique et son utilisation
WO2022182199A1 (fr) Composition contenant un extrait à l'eau chaude de cassis pour prévenir, soulager ou traiter les maladies du foie gras non alcooliques
WO2015105373A1 (fr) Composition pour la prévention ou le traitement de l'asthme, comprenant un extrait de l'e uonymus alatus ou une fraction de ce dernier

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19825300

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19825300

Country of ref document: EP

Kind code of ref document: A1